Broomfield, CO, Jan. 17, 2023 (GLOBE NEWSWIRE) — through NewMediaWire — Aclarion, Inc. (“Aclarion” or the “Firm”) (Nasdaq: ACON, ACONW), a healthcare expertise firm that’s leveraging biomarkers and proprietary augmented intelligence algorithms to assist physicians determine the situation of continual low again ache, introduced at present that George Frey MD, Founding father of the Colorado Complete Backbone Institute, will advise the corporate as a key opinion chief (KOL). Dr. Frey is a famend surgeon and inventor with dozens of US and worldwide patents in medical units, applied sciences, and strategies. Dr. Frey’s experiences as a clinician and entrepreneur will present helpful course to Aclarion.
Persistent low again ache (cLBP) is a number one reason behind opioid habit within the U.S. and the only costliest analysis in the USA. Aclarion’s Nociscan answer is the primary evidence-supported SaaS platform to noninvasively assist physicians distinguish between painful and nonpainful discs within the lumbar spine. Nociscan objectively quantifies chemical biomarkers demonstrated to be related to disc ache. Biomarker knowledge is entered into proprietary algorithms to focus on if a disc could also be a supply of ache. When used with different diagnostic instruments, Nociscan offers important insights into the situation of a affected person’s low again ache, giving physicians readability to optimize therapy methods.
“The nexus of innovation in healthcare and a big, advanced drawback like low again ache is of nice curiosity to me,” mentioned Dr. Frey. “Nociscan is a revolutionary innovation that may simply be scaled, empowering physicians world wide to assist individuals affected by unresolved low again ache. I’m happy to affix the Aclarion mission and contribute to the evolution of spine care by way of an enhanced understanding of the private biomarker insights offered by Nociscan.”
“In 2022, we introduced six key opinion chief physicians which have joined the Aclarion mission. We’re happy to incorporate Dr. Frey with this esteemed group and count on that his expertise will convey a helpful perspective to our KOL program. Moreover, Aclarion introduced a latest addition to our patent portfolio that addresses a key ache biomarker. We stay up for 2023 as we work with our KOL companions to convey Nociscan to sufferers across the globe.”
About Aclarion, Inc.
Aclarion is a healthcare expertise firm that leverages Magnetic Resonance Spectroscopy (“MRS”), proprietary sign processing methods, biomarkers, and augmented intelligence algorithms to optimize scientific therapies. The Firm is first addressing the continual low again ache market with Nociscan, the primary, evidence-supported, SaaS platform to noninvasively assist physicians distinguish between painful and nonpainful discs within the lumbar spine. By a cloud connection, Nociscan receives magnetic resonance spectroscopy (MRS) knowledge from an MRI machine for every lumbar disc being evaluated. Within the cloud, proprietary sign processing methods extract and quantify chemical biomarkers demonstrated to be related to disc ache. Biomarker knowledge is entered into proprietary algorithms to point if a disc could also be a supply of ache. When used with different diagnostic instruments, Nociscan offers important insights into the situation of a affected person’s low again ache, giving physicians readability to optimize therapy methods. For extra data, please go to www.aclarion.com.
Ahead Wanting Statements
This press launch accommodates forward-looking statements inside the that means of the Personal Securities Litigation Reform Act of 1995, Part 27A of the Securities Act of 1933 and Part 21E of the Securities Alternate Act of 1934 in regards to the Firm’s present expectations about future outcomes, efficiency, prospects and alternatives. Statements that aren’t historic information, similar to “anticipates,” “believes” and “expects” or related expressions, are forward-looking statements. These forward-looking statements are primarily based on the present plans and expectations of administration and are topic to quite a few uncertainties and dangers that might considerably have an effect on the Firm’s present plans and expectations, in addition to future outcomes of operations and monetary situation. These and different dangers and uncertainties are mentioned extra totally in our filings with the Securities and Alternate Fee. Readers are inspired to evaluate the part titled “Danger Components” within the Firm’s Prospectus dated April 21, 2022, as filed with the Securities and Alternate Fee on April 25, 2022 below Rule 424(b)(4), in addition to different disclosures contained within the Prospectus and subsequent filings made with the Securities and Alternate Fee. Ahead-looking statements contained on this announcement are made as of this date and the Firm undertakes no obligation to publicly replace or revise any forward-looking statements, whether or not on account of new data, future occasions or in any other case.
Investor Contacts:
Kirin M. Smith
PCG Advisory, Inc.
646.823.8656
ksmith@pcgadvisory.com
Media Contacts:
Jodi Lamberti
SPRIG Consulting
612.812.7477
jodi@sprigconsulting.com
Discussion about this post